Whole-body vibration plus vitamin D for adolescent girls with familial Mediterranean fever
is There an Effect of Addition of Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever
This project will try adding regular whole-body vibration sessions to vitamin D and usual colchicine for girls aged 13–17 with familial Mediterranean fever to see if it improves fitness, muscle strength, and bone mass.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 13 Years to 17 Years |
| Sex | Female |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Giza, Dokki) |
| Trial ID | NCT07130305 on ClinicalTrials.gov |
What this trial studies
Forty adolescent girls with familial Mediterranean fever will be assigned to either a vibration group or a control group, with 20 participants in each arm. All participants will continue their regular colchicine and receive vitamin D daily for six months. The vibration group will also attend three 20-minute whole-body vibration sessions per week for six months. Outcomes measured will include functional performance, cardiorespiratory fitness, muscle strength, and bone mass, with assessments performed at baseline and after six months.
Who should consider this trial
Good fit: Adolescent girls aged 13–17 with a diagnosis of familial Mediterranean fever who are on stable colchicine therapy and can attend regular sessions at the study site are ideal candidates.
Not a fit: Patients with significant cardiac, renal, hepatic, neurological disease, diabetes, or other contraindications to whole-body vibration, or those outside the 13–17 age range, are unlikely to benefit and are excluded.
Why it matters
Potential benefit: If successful, adding whole-body vibration to vitamin D and colchicine could improve fitness, muscle strength, and bone mass in adolescent girls with FMF.
How similar studies have performed: Whole-body vibration and vitamin D have shown benefits for muscle strength and bone density in other populations, but combining them specifically for adolescents with FMF is novel and not previously proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: FMF adolecent girls ages 13 -17 years forty patients Exclusion Criteria: cardiac problems renal problems liver problems diabetes brain problems
Where this trial is running
Giza, Dokki
- Cairo University — Giza, Dokki, Egypt (Recruiting)
Study contacts
- Principal investigator: Ali MA Ismail, lecturer — Cairo University
- Study coordinator: Ali MA Ismail, lecturer
- Email: ali.mohamed@pt.cu.edu.eg
- Phone: 01005154209
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.